Joanne Wuensch: It is. Thank you so much.
Kevin Lobo: Thank you.
Operator: Thank you. Our next question comes from Eric Anderson with Cowen. Please proceed.
Eric Anderson: Hi. This is Eric on for Josh. Can you guys hear me?
Kevin Lobo: Yes. We can.
Glenn Boehnlein: Yeah.
Eric Anderson: Excellent. Maybe thinking about cementless knees. I think about half of your knees are now going in cementless, correct me if I am wrong there. Where do you think that rate could be exiting 2023 and then maybe thinking longer term, what portion of your needs do you think will ultimately be cementless?
Kevin Lobo: Yeah. It’s a great question. So we — we have now — we exited the year over 50% in the U.S. on our knees being cementless. The rate does vary in other countries of the world, but it’s been a steady climb, frankly. They are going to be more conservative on cementless than hips just because it’s weight-bearing versus hips. And do I think it will get to close to 100 like hips? Probably not, just because of bone quality, because it’s weight-bearing. But we have not seen a slowdown. It’s been just this kind of steady march. If you recall a few years ago, it was kind of 30%, then it moved up to 40%, now it’s north of 50% now and I think you will just continue to see that kind of steady climb. Where we will end, I don’t know.
It’s hard to predict, but probably somewhere in the 70%s is kind of what I would — I think it will. So there’s still room to run on cementless, and obviously, we have a proven system that’s delivering terrific long-term results, given that we have done 1 million of them already.
Eric Anderson: Understood. Thanks for that. And apologies if I missed it, but are there any selling day impacts in 2023 that we need to consider?
Kevin Lobo: Yeah. There’s one extra selling day, one less selling day in Q3. But for the full year, it’s the same number of days.
Eric Anderson: Okay. Understood. Thank you.
Kevin Lobo: Okay. Thank you.
Operator: Thank you. And our final question comes from Eric Fleming with Raymond James. You may proceed.
Eric Fleming: Hey, guys. Eric on for Jayson from Raymond James. A quick question on your pricing outlook, are there any segments that have a particular impact or is it across all? Thank you.
Glenn Boehnlein: Yeah. The — obviously, the segment that has the biggest impact is really our MedSurg businesses. We saw Q4 pretty much all positive pricing impacts across MedSurg and so we expect that to continue into 2023. I mean that being said, on the Ortho side, there’s a lot of work around contracts and structures and rebates, and so we are seeing good momentum there as well on pricing. I think the other thing to keep in mind is that, pricing is legacy product over legacy product and so to the extent that we have these product launches, like Kevin was talking about, we generally will launch with premium pricing over the legacy product, but it won’t be included in that pricing statistic. It really gets included in volume. So net-net, I think, you will see probably more favorable pricing coming out of the MedSurg businesses, but we are making great progress on the Ortho side, too.
Operator: Thank you so much. There are no further questions. I will now pass it back over to Kevin Lobo for concluding remarks.
Kevin Lobo: Okay. Great. So, first of all, I want to thank all of you for your patience working through our technical challenges. As you can see, we had a terrific finish to last year, a really good start this year and had a chance to be out with our sales teams across Stryker and I could tell you the momentum is palpable. It feels like it’s going to be a strong year. We, obviously, have — are going to continue to have some challenges around spotting this in the supply chain, but it certainly feels like the worst is behind us as we experienced last year. So I want to thank you all for joining our call. We look forward to sharing our first quarter results with you in April. Thank you.
Operator: This concludes the conference call. Thank you for your participation. You may now disconnect your lines.
